This Core serves two functions. The first is to provide a service to other TCORS investigators by carrying out the analysis of biofluid samples for their studies. The second is to develop new biomarkers of exposure that can be applied to the studies carried out by TCORS investigators, as well as to advance the field. Our laboratory is able to measure alkaloids and toxic substances in both tobacco products and in tobacco smoke. These measurements are needed for biomarker development and to interpret the biomarker data for distinguishing smokeless from smoked tobacco use. These measurements will include other substances in order to explore relationships between toxins and toxin precursors in tobacco and smoke with exposure determined using biomarkers. The improved exposure assessment measures that we expect to develop, and their application to studies carried out by the TCORS, could serve as models for future studies of the risks of new tobacco products and provide scientific basis for their regulation.

Public Health Relevance

The development and validation of biomarkers is a high priority issue for FDA regulation. Studies of tobacco product chemistry with biomarker analyses may provide information on which substances are associated with toxin exposure in humans. Precursors in smoking products that generate toxic substances might provide leads for reducing the toxicity of new products or be targets for regulation. We expect that our studies will result in improved methods for determining human exposure to toxic substances in tobacco and tobacco smoke.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-BDCN-A)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
San Francisco
United States
Zip Code
Dutra, Lauren M; Glantz, Stanton A; Arrazola, René A et al. (2018) Impact of E-Cigarette Minimum Legal Sale Age Laws on Current Cigarette Smoking. J Adolesc Health 62:532-538
Wang, Yingning; Sung, Hai-Yen; Lightwood, James et al. (2018) Health Care Utilization and Expenditures Attributable to Smokeless Tobacco Use Among US Adults. Nicotine Tob Res 20:1359-1368
Glantz, Stanton A (2018) PMI's own in vivo clinical data on biomarkers of potential harm in Americans show that IQOS is not detectably different from conventional cigarettes. Tob Control 27:s9-s12
St Helen, Gideon; Shahid, Marian; Chu, Sherman et al. (2018) Impact of e-liquid flavors on e-cigarette vaping behavior. Drug Alcohol Depend 189:42-48
Ghosh, Arunava; Coakley, Raymond C; Mascenik, Teresa et al. (2018) Chronic E-Cigarette Exposure Alters the Human Bronchial Epithelial Proteome. Am J Respir Crit Care Med 198:67-76
Glantz, Stanton A (2018) Heated tobacco products: the example of IQOS. Tob Control 27:s1-s6
Yao, Tingting; Sung, Hai-Yen; Wang, Yingning et al. (2018) Healthcare Costs of Secondhand Smoke Exposure at Home for U.S. Children. Am J Prev Med :
Alzahrani, Talal; Pena, Ivan; Temesgen, Nardos et al. (2018) Association Between Electronic Cigarette Use and Myocardial Infarction. Am J Prev Med 55:455-461
McKelvey, Karma; Popova, Lucy; Kim, Minji et al. (2018) IQOS labelling will mislead consumers. Tob Control 27:s48-s54
Lempert, Lauren Kass; Glantz, Stanton A (2018) Heated tobacco product regulation under US law and the FCTC. Tob Control 27:s118-s125

Showing the most recent 10 out of 101 publications